In last trading session, Pyxis Oncology Inc (NASDAQ:PYXS) saw 0.42 million shares changing hands with its beta currently measuring 1.07. Company’s recent per share price level of $1.57 trading at -$0.05 or -3.09% at ring of the bell on the day assigns it a market valuation of $93.36M. That closing price of PYXS’s stock is at a discount of -336.31% from its 52-week high price of $6.85 and is indicating a premium of 11.46% from its 52-week low price of $1.39. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.47 million shares which gives us an average trading volume of 1.31 million if we extend that period to 3-months.
For Pyxis Oncology Inc (PYXS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.25. Splitting up the data highlights that, out of 2 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.33 in the current quarter.
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
Upright in the red during last session for losing -3.09%, in the last five days PYXS remained trading in the red while hitting it’s week-highest on Friday, 01/31/25 when the stock touched $1.57 price level, adding 5.99% to its value on the day. Pyxis Oncology Inc’s shares saw a change of 0.64% in year-to-date performance and have moved -1.87% in past 5-day. Pyxis Oncology Inc (NASDAQ:PYXS) showed a performance of 0.64% in past 30-days. Number of shares sold short was 7.42 million shares which calculate 8.86 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8.5 to the stock, which implies a rise of 81.53% to its current value. Analysts have been projecting 7 as a low price target for the stock while placing it at a high target of 10. It follows that stock’s current price would drop -345.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -345.86% for stock’s current value.
Pyxis Oncology Inc (PYXS) estimates and forecasts
Statistics highlight that Pyxis Oncology Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -59.95% of value to its shares in past 6 months, showing an annual growth rate of 44.32% while that of industry is 17.20. Apart from that, the company came raising its revenue forecast for fiscal year 2025.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -118.72% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 40.99% while estimates for its earnings growth in next 5 years are of 12.25%.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
Insiders are in possession of 24.57% of company’s total shares while institution are holding 56.73 percent of that, with stock having share float percentage of 75.20%. Investors also watch the number of corporate investors in a company very closely, which is 56.73% institutions for Pyxis Oncology Inc that are currently holding shares of the company. DEEP TRACK CAPITAL, LP is the top institutional holder at PYXS for having 4.18 million shares of worth $13.85 million. And as of 2024-06-30, it was holding 8.1578 of the company’s outstanding shares.
The second largest institutional holder is LAURION CAPITAL MANAGEMENT LP, which was holding about 3.86 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.5282 of outstanding shares, having a total worth of $12.78 million.
On the other hand, iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Nov 30, 2024 , the former fund manager was holding 1.34 shares of worth $2.1 million or 2.25% of the total outstanding shares. The later fund manager was in possession of 1.29 shares on Sep 30, 2024 , making its stake of worth around $2.03 million in the company or a holder of 2.18% of company’s stock.
